Literature DB >> 11957268

Low risk and high risk human papillomaviruses (HPVs) and cervical cancer in Zimbabwe: epidemiological evidence.

M Chirara1, G A Stanczuk, S A Tswana, L Nystrom, S Bergstrom, S R Moyo, M J Nzara.   

Abstract

OBJECTIVE: To establish the prevalence of detectable low-risk and high-risk, oncogenic HPV types in cervical swabs of women with histologically proven cancer of the cervix.
DESIGN: Cross sectional study.
SETTING: Harare Central and Parirenyatwa Hospitals.
SUBJECTS: 119 women with histologically proven cervical cancer of whom 63 had the degree of differentiation of the tumour reported. MAIN OUTCOME MEASURES: Frequency of infection with high and low-risk human papillomaviruses.
RESULTS: The presence of HPV DNA was demonstrated in 63% (75/119) of cases. Low risk HPVs were present in 26% (31/119) and high-risk HPVs were demonstrated in 51% (61/119) of samples tested. Co-infection with both low-risk and high-risk HPVs was observed in 14% (17/119) of the specimens. High-risk HPVs were detected in 55% (21/38) of poorly differentiated tumours while 60% (15/25) of moderately and well-differentiated tumours showed the presence of high-risk HPVs.
CONCLUSION: High-risk human papillomaviruses are associated with cervical cancer. There was no significant difference in the frequency of high-risk HPV types in women with moderately to well-differentiated tumours and those with poorly-differentiated tumours.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11957268     DOI: 10.4314/cajm.v47i2.8589

Source DB:  PubMed          Journal:  Cent Afr J Med        ISSN: 0008-9176


  2 in total

Review 1.  Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe.

Authors:  Nyasha Chin'ombe; Natasha L Sebata; Vurayai Ruhanya; Hilda T Matarira
Journal:  Infect Agent Cancer       Date:  2014-05-13       Impact factor: 2.965

2.  High-risk HPV genotypes in Zimbabwean women with cervical cancer: Comparative analyses between HIV-negative and HIV-positive women.

Authors:  Oppah Kuguyo; Racheal S Dube Mandishora; Nicholas Ekow Thomford; Rudo Makunike-Mutasa; Charles F B Nhachi; Alice Matimba; Collet Dandara
Journal:  PLoS One       Date:  2021-09-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.